BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
1 
The applicant TopoTarget A/S submitted on 27th July 2005 an application for Marketing Authorisation 
to the European Medicines Agency (EMEA) through the centralised procedure for Savene, which was 
designated  as  an  orphan  medicinal  product  EU/3/01/059  on  19  September  2001.  Savene  was 
designated  as  an  orphan  medicinal  product  in  the  following  indication:    Treatment  of  anthracycline 
extravasation. The estimated prevalence of this condition was approximately 0.03 in 10,000 persons in 
the Community, at the time the application for orphan designation was made.  
The applicant applied for the following indication: “Treatment of anthracycline extravasation”.   
The  application  submitted  is  a  complete  dossier:  composed  of  administrative  information,  complete 
quality  data,  non-clinical  and  clinical  data  based  on  applicants’  own  tests  and  studies  and/or 
bibliographic literature substituting/supporting certain tests or studies. 
Protocol Assistance 
None. 
Licensing status 
The product was not licensed for treatment of anthracycline extravasation in any country at the time of 
submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr Eric Abadie 
Co-Rapporteur:  Dr. Jens Ersbøll  
2 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The application was received by the EMEA on 27 July 2005. 
The procedure started on 17 August 2005. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  
27 October 2005 (Annex 4.1). The Co-Rapporteur's  first Assessment Report was circulated to 
all CHMP members on 1 November 2005.  
During  the  meeting  on  14  December  2005,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 15 December 2005. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
17 February 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on  24 March 2006. 
During the CHMP meeting on 27 April 2006, the CHMP agreed on a List of Outstanding Issues 
to be addressed in writing by the applicant. 
The  applicant  submitted  the  responses  to  the  CHMP  List  of  Outstanding  Issues  on 
2 May 2006. 
The Rapporteurs circulated the Final Assessment Report on the applicant’s responses to the List 
of Outstanding Issues to all CHMP members on 19 May 2006 
During  the  meeting  on    29  May-1  June  2006,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Savene on 1 June 2006. The applicant provided the letter 
of undertaking on the follow-up measures to be fulfilled post-authorisation on 23 May 2006. 
The  European  Commission  granted  a  marketing  authorisation  valid  throughout  the  European 
Union for Savene on 28 July 2006. 
1/1 
©EMEA 2006 
 
 
 
 
 
 
